Xeris Biopharma Holdings, Inc. (XERS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Xeris Biopharma Holdings, Inc. (XERS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 58/100 — a percentile rank of Xeris Biopharma Holdings, Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $1.7B |
| P / S | 5.0× |
| EV / EBITDA | 37.3× |
| Gross margin | 86.6% |
| Operating margin | 10.9% |
| Net margin | -5.1% |
| Return on equity | 176.3% |
| ROIC | 30.2% |
| Revenue growth | 36.3% |
| Debt / equity | -25.9× |
| Dividend yield | 0.0% |
Is Xeris Biopharma Holdings, Inc. overvalued? P/S looks overvalued vs its 5-year range.
Independent of the events above — derived from Xeris Biopharma Holdings, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact